RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Core Points - RedHill Biopharma Ltd. received a Notification Letter from Nasdaq indicating non-compliance with Listing Rule 5550(b)(1) due to a stockholders' deficit of $4,683,000 as of December 31, 2024 [1][2] - The company has 45 days to submit a compliance plan to Nasdaq, with the possibility of an extension of up to 180 days if the plan is accepted [3][4] - The Notification Letter does not currently affect the company's listing or business operations [1][3] Company Overview - RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [5] - Key products include Talicia, an FDA-approved drug for H. pylori infection, and several late-stage development programs targeting various diseases [5] - The company is exploring options to regain compliance with Nasdaq listing requirements and intends to submit its compliance plan promptly [4]